STALICLA at Synchrony 2022
We are very pleased to share the replay of STALICLA’s expert presentation at the Synchrony 2022 held on 2-4 December at Pleasanton, CA, USA.
Stalicla’s CEO and founder, Lynn Durham, was contributing on Friday, December 2nd in the Pathways to the FDA Approval – Challenges and Guidance roundtable panel discussion.
On Saturday, December 3rd at the industry session – Lynn Durham and Baltazar Gomez-Mancilla were presenting the results of STALICLA’s STP1 Phase 1b clinical trial.